一株HGPRT缺陷型小鼠肺癌细胞株的建立及其生物学性质  

An HGPRT defective mouse lung cancer cell line and its biological characteristics

作　　者：林苹[1] 陆燕蓉[1] 周宏远[1] 张洁[1] 黄孝忠[1] 

机构地区：[1]华西医科大学附属第一医院肿瘤中心,肿瘤研究所,成都610041

出　　处：《肺癌杂志》1999年第1期5-7,共3页

基　　金：国家自然科学基金! (3980 0 1 4 7);卫生部基金 !(96 1 2 36)资助

摘　　要：目的　为研制肺癌疫苗提供适合细胞融合的抗原细胞。方法　用8氮鸟嘌呤(8AG)从小鼠肺癌细胞LA795渐进诱导次黄嘌呤鸟嘌呤转磷酸核糖基酶(HGPRT)缺陷型细胞株ALA9702,并鉴定其生物学性质及成瘤性。结果　ALA9702细胞在20μg/ml8AG培养液中生长了一年,在HAT培养液中不能形成集落,并保持了来源细胞LA795的生物学性质及成瘤性。结论　ALA9702细胞株稳定表现为HGPRT缺陷型小鼠肺癌细胞。Objective To provide antigenic cells suitable for cell fusion to preparing lung cancer vaccine. Methods An HGPRT (hypoxanthine guanidine phosphoribosyl transferase) defective cell line, ALA 9702 , was gradually induced by 8 azaguanine (8 AG) from mouse lung cancer cell line, LA 795 . The biological characteristics and carcinogenicity of ALA 9702 cells have been appraised both in vivo and in vitro. Results ALA 9702 cells have been cultured over one year in medium containing 20μg/ml 8 AG, and maintained their biologic characteristics and carcinogenicity of the original cells, LA 795 cells. Conclusion ALA 9702 cell line presents as stabile HGPRT defective mouse lung cancer cell. It will provide useful antigenic cells for establishment of effective specific lung cancer vaccine therapy.

关 键 词：HGPRT缺陷型 肺癌细胞株 生物学性质 小鼠 肺癌疫苗 

分 类 号：R734.201[医药卫生—肿瘤] R392.7[医药卫生—临床医学]